Canada markets closed

AXSM Sep 2024 110.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.95000.0000 (0.00%)
As of 10:44AM EDT. Market open.
Full screen
Previous Close0.9500
Open0.9500
Bid0.0000
Ask0.0000
Strike110.00
Expire Date2024-09-20
Day's Range0.9500 - 0.9500
Contract RangeN/A
Volume1
Open InterestN/A
  • GlobeNewswire

    Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New J

  • GlobeNewswire

    Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

    NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is joining the migraine advocacy community to raise awareness of unmet patient needs during Migraine & Headache Awareness Month this June. “Education plays a crucial role in addressing the stigma associated with migraine, a complex neurological disorder often mis

  • GlobeNewswire

    Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

    NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is supporting Alzheimer’s & Brain Awareness Month this June, to help increase awareness and understanding of the challenges Alzheimer’s disease (AD) presents to patients, their caregivers, and their loved ones, and the importance of brain and mental health as cor